App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycaemic Control in Type 2 Diabetes: A Prospective Observational Cohort Study
ABSTRACT
Background:
Digital therapeutics integrating continuous glucose monitoring (CGM) with personalised lifestyle coaching can enhance glycaemic control in individuals with type 2 diabetes mellitus (T2DM). However, real-world evidence evaluating such multi-component interventions remains limited.
Objective:
This study was conducted aimed to evaluate the effectiveness of the 90-day Goodflip programme, an app-based lifestyle intervention, on glycaemic, anthropometric, lipid, quality-of-life (QoL), and Health Economics and Outcomes Research (HEOR) outcomes in adults with T2DM.
Methods:
A prospective observational cohort study was conducted among adults aged ≥18 years with mildly uncontrolled T2DM (HbA1c 7.5–9.5%). The intervention combined CGM-guided personalised diet, exercise, and cognitive behavioural therapy (CBT) plans delivered via the MyTatva mobile app, supported by multidisciplinary coaching and follow-up calls on days 15, 30, and 60. Primary outcomes were changes in HbA1c, fasting plasma glucose (FPG), postprandial glucose (PPG), and CGM metrics; secondary outcomes included lipid profile, anthropometric indices, QoL, and behavioural metrics.
Results:
Eighteen participants (mean age 49.45 years; 61.1% male) completed the programme. Mean HbA1c reduced by 0.59% (p=0.050), with PPG decreasing by 25.42 mg/dL (p=0.060) and time-in-range improving by 9.98%. Modest, non-significant reductions occurred in LDL-C (−8.38 mg/dL), body fat (−1.13 kg), and waist circumference (−1.56 cm). QoL improved significantly in sleep quality (p=0.046) and other behavioural domains.
Conclusions:
Integrating CGM with app-based, CBT-guided coaching produced clinically meaningful improvements in glycaemic and behavioural outcomes, supporting its use as an effective adjunct to conventional diabetes care. Clinical Trial: The study protocol was reviewed and approved by the Institutional Ethics Committee of Aatman Hospital (EC/NEW/INST/2021/11802) and registered with the Clinical Trials Registry–India (CTRI/2024/08/071850). All study procedures adhered to the principles outlined in the Declaration of Helsinki and its subsequent amendments, and electronic informed consent was obtained from each participant prior to enrolment.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.